• Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Ask AI
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)
    • Services
      • Equity Reports (Analyst-Ready)
      • Visibility Upgrades (Quartely + As needed)
      • Investor Mapping
    • Press
    • Ask AI
    • Contact
    • English
      • Deutsch (German)
      • 日本語 (Japanese)
  • info@vasro.de
  • +49 (0)69 90 28 39 81
  • Call us Mon - Fri: 8:30 AM - 6:00 PM
VASRO GmbH
VASRO GmbH
  • Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Ask AI
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)

Press

VASRO GmbH > Press
VASRO GmbH

Solar systems in Bavaria: LCOE, CAPEX/OPEX & subsidy overview for SMEs

  • September 29, 2025
  • Energy
Dachsolaranlagen in Bayern: LCOE, CAPEX/OPEX und aktuelle Förderungen für KMU. So senken Unternehmen ihre Stromkosten und profitieren von Zuschüssen.
Continue Reading
VASRO GmbH

CDMO Sourcing in Europe: Who Can Make mRNA at 1–10 kg Scale?

  • September 26, 2025
  • Pharma & Biotech
CDMO Sourcing in Europe: SEQENS, Touchlight, Polymun, and Rentschler Biopharma offer mRNA manufacturing at 1–10 kg scale with GMP compliance.
Continue Reading
VASRO GmbH

Tech Equity Scoring: Using Big Data for Portfolio Optimization

  • September 25, 2025
  • Unkategorisiert
Tech equity scoring leverages big data to optimize portfolios, enhance risk-adjusted returns, and support smarter investment decisions in technology stocks.
Continue Reading
VASRO GmbH

Renewables vs. Fossil Fuels: Equity Report Insights on Energy Sector Shifts

  • September 24, 2025
  • Energy
Renewables vs. Fossil Fuels: Equity reports reveal sector shifts, investment trends, and the impact on costs, access, and sustainability in energy.
Continue Reading
VASRO GmbH

Cyber Insurance in the EU

  • September 23, 2025
  • Tech
Cyber Insurance in the EU protects businesses from cyber threats, regulatory fines, and data breaches while supporting compliance and business continuity.
Continue Reading
VASRO GmbH

Biotech IPOs 2025: Equity Report Predictions and Market Opportunities

  • September 22, 2025
  • Pharma & Biotech
Biotech IPOs 2025 forecast a selective market favoring clinical maturity, innovation, and robust equity opportunities for investors and companies.
Continue Reading
VASRO GmbH

Biotech Regulatory Waves: Equity Report Impacts of FDA Approvals in 2025

  • September 10, 2025
  • Pharma & Biotech
Biotech regulatory waves in 2025 drive equity report shifts as FDA approvals reshape valuations, investor sentiment, and market volatility across the sector.
Continue Reading
VASRO GmbH

Equity Report FAQ: 10 Common Investor Questions Answered for 2025

  • September 9, 2025
  • Energy, Commodity, Real Estate, Pharma & Biotech, Tech
Equity Report FAQ answers 10 top investor questions for 2025, covering key metrics, risk assessment, analyst ratings, and how to use equity reports effectively.
Continue Reading
VASRO GmbH

Cross-Sector Equity Comparison: Pharma vs. Tech vs. Energy in 2025 and beyond

  • September 8, 2025
  • Energy, Pharma & Biotech, Tech
Cross-Sector Equity Comparison: Analyze pharma, tech, and energy equities for 2025 and beyond by growth, risk, valuation, innovation, and ESG performance.
Continue Reading
VASRO GmbH

PPA-Preise für den Mittelstand: Wie deutsche Hersteller 5–10-jährige erneuerbare PPAs strukturieren

  • September 5, 2025
  • Tech
PPA-Preise für den Mittelstand: Erfahre, wie deutsche Hersteller 5–10-jährige erneuerbare PPAs strukturieren und welche Preisbereiche aktuell marktüblich sind.
Continue Reading

Posts pagination

Previous 1 … 11 12 13 … 37 Next

Search

Categories

  • Energy
  • Equity Analysis reports
  • Equity Research Coverage
  • Market Intelligence
  • Pharma & Biotech
  • Tech
  • Unkategorisiert

Recent Posts

Sirnaomics Ltd.: The RNAimmune Money Is In, and the FDA Has Answered in Writing on STP705 October 12, 2026
Ainos, Inc.: A Partner Pays for VELDONA, and Ainos Keeps the Platform September 29, 2026
Ainos Inc: A Front-End Customer Starts Ordering, and the Dataset Passes a Billion September 16, 2026
Ainos, Inc.: Three Patents Approved in Japan, and a Dataset Gathering Pace September 11, 2026
Baladna: The Capital Is Raised, Algeria Is Building – VASRO Reiterates BUY at QAR 2.33 September 7, 2026
VASRO GmbH
VASRO GmbH specializes in equity analysis, market intelligence, and investment strategy for the pharmaceutical, biotechnology, and IT sectors. We deliver tailored insights to drive informed investment decisions and achieve exceptional results.

Discover More

Contact Info

  • Am Hauptbahnhof 16, 60329 Frankfurt am Main, Germany
  • +49 (0)69 90 28 39 81
  • info@vasro.de
  • 8:30 AM - 6:00 PM

Navigation

  • Imprint
  • Privacy Policy
  • Change privacy settings
  • Application
  • About
  • FAQ

©copyright 2025 VASRO GmbH.